Tiede is one of several industry executives who gathered to discuss companies' obstacles for full-blown EDC implementation—and also to examine the technology's benefits. Hosted by Pharmaceutical Executive and management consultancy Campbell Alliance, the executive roundtable brought together a group of early EDC adopters, all of whom had offered thought leadership to the industry and their company in pushing forward the technology.
The conversation was moderated by Pharm Exec's editor-in-chief Patrick Clinton.
CLINTON: Most companies know the benefits of EDC—the real-time access to data, faster study completion, and cost savings are clear. Still, some leaders are hesitant to fully integrate EDC into their organizations. Why should they integrate EDC into a clinical trials process that has worked for them for years?
TYSON: One of the messages we tell senior management is that EDC has a lot of tremendous benefits, but you have to be patient if you want to see them. You're not going to see it in year one. It's just a classic case of people needing to be aware that with any kind of major change, you have a ramp-up curve before you see any benefit.
OLSEN: If you look at the conversation at EDC conferences four years ago, everyone was saying, "Let's try it, let's pilot it." Now you go to conferences and people are saying, "I'm in this stage of an implementation," "We're at 90 percent already," or "We're in the year where we're moving from 25 to 75 percent." Companies are now in that stage where they've committed to it, and we're somewhere along a continuum of getting past the pilot and into whatever is full mutation for an organization. There's a growing understanding through our peer community and a sense of community among the pharma companies.